News

An early feasibility study evaluating Third Pole Therapeutics‘ eNOfit — a miniaturized, portable inhaled nitric oxide (iNO) delivery system to treat pulmonary hypertension (PH) associated with interstitial lung disease — has dosed its first patient, the company announced. The goal for the investigational device is to provide patients…

INOmax EVOLV DS, a device to deliver nitric oxide gas by inhalation to newborns with pulmonary hypertension (PH), is expected to be available in hospitals in the U.S. in the first half of 2024. The U.S. Food and Drug Administration (FDA) has cleared the next-generation device, developed by…

Raymond Benza, MD, has been selected to be director of pulmonary hypertension (PH) for the Mount Sinai Health System, In this newly created position, Benza will seek to advance and standardize care for PH patients and further develop research in the progressive disorder that is associated with high blood…

Babies with persistent pulmonary hypertension of the newborn (PPHN) started quickly on treatment with prostaglandin E1 (PGE1) — which lowers blood pressure by allowing blood vessels to relax and open up — show a better working heart and a lesser need of extra oxygen, a study reports. “Importantly, the…

People with pulmonary arterial hypertension (PAH) who have problems breathing while they’re sleeping — causing nocturnal hypoxemia, or oxygen levels in the blood to drop during the night — are nearly twice as likely as patients without such difficulty to experience clinical worsening, a study found. “The rate of…

When choosing a treatment regimen, people with pulmonary arterial hypertension (PAH) consider the impact on physical limitations and survival at three years as the most important parameters to consider, according to a study in Germany. Meanwhile, unplanned hospitalizations within three years and short-term side effects were reported as less…

Lower levels of apolipoprotein A-I (ApoA-I), a component of high-density lipoprotein (HDL), or “good cholesterol,” is a significant predictor of mortality in people with pulmonary arterial hypertension (PAH), a study suggests. “Our study identified the significance of ApoA-I as a biomarker for predicting the survival outcome of PAH patients,”…

A protein called SPHK2 helps to drive pulmonary hypertension (PH) by changing the epigenetic profiles of cells in blood vessels, a study reports. Epigenetics refers to changes in gene activity that do not change the genetic code itself. As such, study findings imply that blocking SPHK2 or otherwise reversing…

The Phase 2b portion of the IMPAHCT clinical trial, which is testing multiple doses of the inhaled imatinib formulation AV-101 against a placebo in adults with pulmonary arterial hypertension (PAH), has finished enrollment. Top-line results are expected in June 2024, according to AV-101’s developer, Aerovate Therapeutics. “The completion…

Treating children with Revatio (sildenafil) reduced pulmonary arterial pressure after surgery for congenital heart disease (CHD), according to a new analysis. The pulmonary hypertension (PH) treatment, given between one and two weeks before surgery, reduced how long cardiopulmonary bypass — a procedure that takes over the functions of the…

The CorVista System, a point of care device that applies a machine learning algorithm to decode data, can predict the presence of pulmonary hypertension in patients with new-onset symptoms of cardiovascular disease, a study shows. The device’s algorithm performed about as well as transthoracic echocardiography, or TTE, a standard…

Tenax Therapeutics is planning to soon launch a Phase 3 clinical trial of TNX-103, an oral formulation of levosimendan, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The company announced it received clearance from the U.S. Food and Drug Administration (FDA) to conduct…